161 related articles for article (PubMed ID: 12665648)
21. Galectin-3 and HBME-1 improve the accuracy of core biopsy in indeterminate thyroid nodules.
Trimboli P; Guidobaldi L; Amendola S; Nasrollah N; Romanelli F; Attanasio D; Ramacciato G; Saggiorato E; Valabrega S; Crescenzi A
Endocrine; 2016 Apr; 52(1):39-45. PubMed ID: 26142180
[TBL] [Abstract][Full Text] [Related]
22. Expression of HBME-1 and CD56 in follicular variant of papillary carcinoma in children: An immunohistochemical study and their diagnostic utility.
Skaria PE; Ahmed AA; Yin H; Nicol K; Reid KJ; Singh V
Pathol Res Pract; 2019 May; 215(5):880-884. PubMed ID: 30711197
[TBL] [Abstract][Full Text] [Related]
23. RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma.
Nikiforova MN; Lynch RA; Biddinger PW; Alexander EK; Dorn GW; Tallini G; Kroll TG; Nikiforov YE
J Clin Endocrinol Metab; 2003 May; 88(5):2318-26. PubMed ID: 12727991
[TBL] [Abstract][Full Text] [Related]
24. The use of a combination of galectin-3 and thyroid peroxidase for the diagnosis and prognosis of thyroid cancer.
Weber KB; Shroyer KR; Heinz DE; Nawaz S; Said MS; Haugen BR
Am J Clin Pathol; 2004 Oct; 122(4):524-31. PubMed ID: 15487449
[TBL] [Abstract][Full Text] [Related]
25. Proteomic identification of new biomarkers and application in thyroid cytology.
Torres-Cabala C; Bibbo M; Panizo-Santos A; Barazi H; Krutzsch H; Roberts DD; Merino MJ
Acta Cytol; 2006; 50(5):518-28. PubMed ID: 17017437
[TBL] [Abstract][Full Text] [Related]
26. Galectin-3 and HBME-1 expression in oncocytic cell tumors of the thyroid.
Volante M; Bozzalla-Cassione F; DePompa R; Saggiorato E; Bartolazzi A; Orlandi F; Papotti M
Virchows Arch; 2004 Aug; 445(2):183-8. PubMed ID: 15252732
[TBL] [Abstract][Full Text] [Related]
27. Role of cd56 and e-cadherin expression in the differential diagnosis of papillary thyroid carcinoma and suspected follicular-patterned lesions of the thyroid: the prognostic importance of e-cadherin.
Ceyran AB; Şenol S; Şimşek BÇ; Sağıroğlu J; Aydın A
Int J Clin Exp Pathol; 2015; 8(4):3670-80. PubMed ID: 26097548
[TBL] [Abstract][Full Text] [Related]
28. Molecular markers in thyroid fine-needle aspiration biopsy: a prospective study.
Franco C; Martínez V; Allamand JP; Medina F; Glasinovic A; Osorio M; Schachter D
Appl Immunohistochem Mol Morphol; 2009 May; 17(3):211-5. PubMed ID: 19384080
[TBL] [Abstract][Full Text] [Related]
29. Comparison of proliferating cell nuclear antigen, thyroid transcription factor-1, Ki-67, p63, p53 and high-molecular weight cytokeratin expressions in papillary thyroid carcinoma, follicular carcinoma, and follicular adenoma.
Tan A; Etit D; Bayol U; Altinel D; Tan S
Ann Diagn Pathol; 2011 Apr; 15(2):108-16. PubMed ID: 21315633
[TBL] [Abstract][Full Text] [Related]
30. Contribution of immunocytochemical stainings for galectin-3, CD44, and HBME1 to fine-needle aspiration cytology diagnosis of papillary thyroid carcinoma.
Das DK; Al-Waheeb SK; George SS; Haji BI; Mallik MK
Diagn Cytopathol; 2014 Jun; 42(6):498-505. PubMed ID: 24273003
[TBL] [Abstract][Full Text] [Related]
31. Differential diagnostic significance of HBME-1, CK19 and S100 in various thyroid lesions.
Palo S; Biligi DS
Malays J Pathol; 2017 Apr; 39(1):55-67. PubMed ID: 28413206
[TBL] [Abstract][Full Text] [Related]
32. Distinction between papillary thyroid hyperplasia and papillary thyroid carcinoma by immunohistochemical staining for cytokeratin 19, galectin-3, and HBME-1.
Casey MB; Lohse CM; Lloyd RV
Endocr Pathol; 2003; 14(1):55-60. PubMed ID: 12746563
[TBL] [Abstract][Full Text] [Related]
33. Differential expression of galectin-3 in medullary thyroid carcinoma and C-cell hyperplasia.
Faggiano A; Talbot M; Lacroix L; Bidart JM; Baudin E; Schlumberger M; Caillou B
Clin Endocrinol (Oxf); 2002 Dec; 57(6):813-9. PubMed ID: 12460332
[TBL] [Abstract][Full Text] [Related]
34. [Expression of TTF-1 in thyroid tumors originating from follicular epithelium and its correlation with expression of RET, galectin-3 and mucin-1 genes].
Chen Y; Zhu M; Zhou X; Lin W; Ni C; Li F; Zhang S; Gong Z
Zhonghua Yi Xue Za Zhi; 2002 Feb; 82(4):257-61. PubMed ID: 11953175
[TBL] [Abstract][Full Text] [Related]
35. Atypical thyroid nodules express both HBME-1 and Galectin-3, two phenotypic markers of papillary thyroid carcinoma.
Coli A; Bigotti G; Parente P; Federico F; Castri F; Massi G
J Exp Clin Cancer Res; 2007 Jun; 26(2):221-7. PubMed ID: 17725102
[TBL] [Abstract][Full Text] [Related]
36. [Usefulness of CK19, HBME-1 and galectin-3 expressions in differential diagnosis of thyroid papillary microcarcinoma from benign lesions].
Tong J; Wang Y; Da JP
Zhonghua Zhong Liu Za Zhi; 2011 Aug; 33(8):599-604. PubMed ID: 22325220
[TBL] [Abstract][Full Text] [Related]
37. Fine-needle aspiration biopsy of papillary thyroid carcinoma: diagnostic utility of cytokeratin 19 immunostaining.
Nasser SM; Pitman MB; Pilch BZ; Faquin WC
Cancer; 2000 Oct; 90(5):307-11. PubMed ID: 11038428
[TBL] [Abstract][Full Text] [Related]
38. Combined immunostaining with galectin-3, fibronectin-1, CITED-1, Hector Battifora mesothelial-1, cytokeratin-19, peroxisome proliferator-activated receptor-{gamma}, and sodium/iodide symporter antibodies for the differential diagnosis of non-medullary thyroid carcinoma.
Liu YY; Morreau H; Kievit J; Romijn JA; Carrasco N; Smit JW
Eur J Endocrinol; 2008 Mar; 158(3):375-84. PubMed ID: 18299472
[TBL] [Abstract][Full Text] [Related]
39. Role of galectin-3 immunodetection in the cytological diagnosis of thyroid cystic papillary carcinoma.
Papotti M; Volante M; Saggiorato E; Deandreis D; Veltri A; Orlandi F
Eur J Endocrinol; 2002 Oct; 147(4):515-21. PubMed ID: 12370115
[TBL] [Abstract][Full Text] [Related]
40. Global DNA methylation evaluation: potential complementary marker in differential diagnosis of thyroid neoplasia.
Galusca B; Dumollard JM; Lassandre S; Niveleau A; Prades JM; Estour B; Peoc'h M
Virchows Arch; 2005 Jul; 447(1):18-23. PubMed ID: 15891902
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
